|
Name |
2-(Trifluoromethyl)piperazine
|
Molecular Formula | C5H9F3N2 | |
IUPAC Name* |
2-(trifluoromethyl)piperazine
|
|
SMILES |
C1CNC(CN1)C(F)(F)F
|
|
InChI |
InChI=1S/C5H9F3N2/c6-5(7,8)4-3-9-1-2-10-4/h4,9-10H,1-3H2
|
|
InChIKey |
YNEJOOCZWXGXDU-UHFFFAOYSA-N
|
|
Synonyms |
2-(Trifluoromethyl)piperazine; 131922-05-9; 2-trifluoromethyl-piperazine; (+/-)-2-(trifluoromethyl)piperazine; PIPERAZINE, 2-(TRIFLUOROMETHYL)-; Piperazine, 2-(trifluoromethyl)- (9CI); MFCD07373382; ()-2-(Trifluoromethyl)piperazine; 2trifluoromethylpiperazine; m-trifluoromethylpiperazine; 2-trifluoromethylpiperazine; SCHEMBL18029; DTXSID10594369; AMY18731; 2-(Trifluoromethyl)piperazine, 95%; AKOS005255698; AB36961; AB36963; AB36966; CS-W014339; FS-2154; EN300-73254; S11290; A849545
|
|
CAS | 131922-05-9 | |
PubChem CID | 18519725 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 154.13 | ALogp: | 0.3 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 24.1 | Aromatic Rings: | 1 |
Heavy Atoms: | 10 | QED Weighted: | 0.531 |
Caco-2 Permeability: | -5.04 | MDCK Permeability: | 0.00000466 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.509 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.001 |
30% Bioavailability (F30%): | 0.002 |
Blood-Brain-Barrier Penetration (BBB): | 0.435 | Plasma Protein Binding (PPB): | 19.44% |
Volume Distribution (VD): | 0.856 | Fu: | 85.64% |
CYP1A2-inhibitor: | 0.084 | CYP1A2-substrate: | 0.09 |
CYP2C19-inhibitor: | 0.044 | CYP2C19-substrate: | 0.892 |
CYP2C9-inhibitor: | 0.007 | CYP2C9-substrate: | 0.089 |
CYP2D6-inhibitor: | 0.057 | CYP2D6-substrate: | 0.745 |
CYP3A4-inhibitor: | 0.033 | CYP3A4-substrate: | 0.576 |
Clearance (CL): | 7.739 | Half-life (T1/2): | 0.249 |
hERG Blockers: | 0.018 | Human Hepatotoxicity (H-HT): | 0.946 |
Drug-inuced Liver Injury (DILI): | 0.03 | AMES Toxicity: | 0.082 |
Rat Oral Acute Toxicity: | 0.233 | Maximum Recommended Daily Dose: | 0.897 |
Skin Sensitization: | 0.408 | Carcinogencity: | 0.241 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
Respiratory Toxicity: | 0.912 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000853 | 0.167 | D01XLM | 0.250 | ||||
ENC000100 | 0.159 | D0D8VE | 0.200 | ||||
ENC004464 | 0.129 | D0DZ3X | 0.167 | ||||
ENC000450 | 0.119 | D0GQ7K | 0.167 | ||||
ENC000183 | 0.100 | D01JMC | 0.164 | ||||
ENC000511 | 0.098 | D0DP6L | 0.159 | ||||
ENC001281 | 0.096 | D0H4GN | 0.159 | ||||
ENC000882 | 0.094 | D03DAP | 0.156 | ||||
ENC000991 | 0.094 | D0G5BK | 0.156 | ||||
ENC001229 | 0.094 | D07HVY | 0.151 |